AU2012312902B2 - Estrogen receptor ligands and methods of use thereof - Google Patents
Estrogen receptor ligands and methods of use thereof Download PDFInfo
- Publication number
- AU2012312902B2 AU2012312902B2 AU2012312902A AU2012312902A AU2012312902B2 AU 2012312902 B2 AU2012312902 B2 AU 2012312902B2 AU 2012312902 A AU2012312902 A AU 2012312902A AU 2012312902 A AU2012312902 A AU 2012312902A AU 2012312902 B2 AU2012312902 B2 AU 2012312902B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- another embodiment
- prostate cancer
- levels
- crpc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/215,679 US9427418B2 (en) | 2009-02-23 | 2011-08-23 | Estrogen receptor ligands and methods of use thereof |
| US13/215,679 | 2011-08-23 | ||
| PCT/US2012/052141 WO2013043304A1 (en) | 2009-02-23 | 2012-08-23 | Estrogen receptor ligands and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012312902A1 AU2012312902A1 (en) | 2013-05-23 |
| AU2012312902B2 true AU2012312902B2 (en) | 2016-03-17 |
Family
ID=48444651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012312902A Ceased AU2012312902B2 (en) | 2011-08-23 | 2012-08-23 | Estrogen receptor ligands and methods of use thereof |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2747562A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014524479A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140064906A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103957706A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012312902B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2845890A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL231070A0 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN01959A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014002105A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2014111060A (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3688008A1 (en) * | 2017-09-27 | 2020-08-05 | TargImmune Therapeutics AG | Castration resistant prostate cancer |
| SG11202107712SA (en) * | 2019-01-30 | 2021-08-30 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| US20230174662A1 (en) * | 2019-02-01 | 2023-06-08 | Fondazione Per L'istituto Oncologico Di Ricerca (Ior) | Methods of treating castrate-resistant prostate cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070265296A1 (en) * | 2005-11-28 | 2007-11-15 | Dalton James T | Nuclear receptor binding agents |
| US20100267773A1 (en) * | 2005-11-28 | 2010-10-21 | Dalton James T | Estrogen receptor ligands and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2824517A1 (en) * | 2005-11-28 | 2007-05-31 | Gtx, Inc. | Nuclear receptor binding agents |
| WO2010096801A1 (en) * | 2009-02-23 | 2010-08-26 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
-
2012
- 2012-08-23 MX MX2014002105A patent/MX2014002105A/es unknown
- 2012-08-23 RU RU2014111060/15A patent/RU2014111060A/ru not_active Application Discontinuation
- 2012-08-23 CA CA2845890A patent/CA2845890A1/en not_active Abandoned
- 2012-08-23 IN IN1959DEN2014 patent/IN2014DN01959A/en unknown
- 2012-08-23 CN CN201280051979.4A patent/CN103957706A/zh active Pending
- 2012-08-23 EP EP12834287.0A patent/EP2747562A4/en not_active Withdrawn
- 2012-08-23 JP JP2014527312A patent/JP2014524479A/ja active Pending
- 2012-08-23 KR KR1020147007549A patent/KR20140064906A/ko not_active Withdrawn
- 2012-08-23 AU AU2012312902A patent/AU2012312902B2/en not_active Ceased
-
2014
- 2014-02-20 IL IL231070A patent/IL231070A0/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070265296A1 (en) * | 2005-11-28 | 2007-11-15 | Dalton James T | Nuclear receptor binding agents |
| US20100267773A1 (en) * | 2005-11-28 | 2010-10-21 | Dalton James T | Estrogen receptor ligands and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014111060A (ru) | 2015-09-27 |
| EP2747562A4 (en) | 2015-05-06 |
| CN103957706A (zh) | 2014-07-30 |
| IN2014DN01959A (cg-RX-API-DMAC7.html) | 2015-05-15 |
| MX2014002105A (es) | 2014-09-25 |
| AU2012312902A1 (en) | 2013-05-23 |
| JP2014524479A (ja) | 2014-09-22 |
| KR20140064906A (ko) | 2014-05-28 |
| IL231070A0 (en) | 2014-03-31 |
| CA2845890A1 (en) | 2013-03-28 |
| EP2747562A1 (en) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2753436C (en) | Estrogen receptor ligands and methods of use thereof | |
| US9051267B2 (en) | Estrogen receptor ligands and methods of use thereof | |
| US9427418B2 (en) | Estrogen receptor ligands and methods of use thereof | |
| US20140187641A1 (en) | Estrogen receptor ligands and methods of use thereof | |
| US9409856B2 (en) | Estrogen receptor ligands and methods of use thereof | |
| AU2018201450A1 (en) | A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS) | |
| AU2006318400C1 (en) | Nuclear receptor binding agents | |
| US20180118663A1 (en) | Selective androgen receptor degrader (sard) ligands and methods of use thereof | |
| US8637706B2 (en) | Nuclear receptor binding agents | |
| US9624161B2 (en) | Estrogen receptor ligands and methods of use thereof | |
| CA3173036A1 (en) | Selective androgen receptor degrader (sard) ligands and methods of use thereof | |
| US20140057985A1 (en) | Estrogen receptor ligands and methods of use thereof | |
| AU2012312902A1 (en) | Estrogen receptor ligands and methods of use thereof | |
| US20140057946A1 (en) | Estrogen receptor ligands and methods of use thereof | |
| WO2013043304A1 (en) | Estrogen receptor ligands and methods of use thereof | |
| AU2010215809B2 (en) | Estrogen receptor ligands and methods of use thereof | |
| AU2011226856B2 (en) | Nuclear receptor binding agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |